Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-143 in CKD Patients
NCT03581071Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TS-143 in anemia of chronic kidney disease (CKD-A) (5 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Incidence of adverse events at 8 days, Plasma concentrations of unchanged form at 7 days and 4 more. Started Oct 2016; status: completed.
02
Drugs
TS-143
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03581071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581071.